Drug Trial Radar · NCT05291234
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Aug 15, 2022
Primary completion
Nov 19, 2025
Study completion Nov 19, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-916 is in treating early AD. Adverse events, change in disease activity, and how ABBV-916 moves through body of participants will be assessed. ABBV-916 is an investigational drug being developed for the treatment of early AD. This study is conducted in 2 stages. Stage A is a multiple ascending dose study. There is a 1 in 4 chance that participants are assigned to receive placebo. Stage B is a proof-of-concept study. In Stage B, there is a 1 in 5 chance that participants will be assigned to receive placebo. The first 6 months of this study are "double-blind," which means that neither the trial participant nor the study doctors know which treatments will be given. This will be followed by a 2-year extension period in which all participants will receive ABBV-916. Approximately 195 participants aged 50-90 years will be enrolled in about 90 sites across the world. Participants will receive intravenous (IV) doses of ABBV-916 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for an additional 16 weeks. Participants will have the option of participating in a 2-year, open-label, Extension Period receiving IV ABBV-916. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, magnetic resonance imaging (MRI), blood tests, checking for side effects and completing questionnaires.
Conditions
- Alzheimer's Disease (AD)
Interventions
ABBV-916Drug
Intravenous administration
PlaceboDrug
Intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to approximately 160 weeks
- Stage A: Maximum Observed Serum Concentration (Cmax) for Multiple Ascending Dose of ABBV-916Time frame: Up to approximately 24 weeks
- Stage A: Time to Cmax (Tmax) for Multiple Ascending Dose of ABBV-916Time frame: Up to approximately 24 weeks
- Stage A: Apparent Terminal Phase Elimination Rate Constant (β) of ABBV-916Time frame: Up to approximately 24 weeks
- Stage A: Terminal Phase Elimination Half-Life (t1/2) of ABBV-916Time frame: Up to approximately 24 weeks
- Stage A: Trough Serum Concentration (Ctrough) of ABBV-916 at the End of a Dosing IntervalTime frame: Up to approximately 24 weeks
- Stage A: Area Under the Concentration-Time Curve (AUC) of ABBV-916Time frame: Up to approximately 24 weeks
- Stage A: Cerebrospinal Fluid (CSF) Concentration as a Measure of ABBV-916 Crossing the Blood Brain BarrierTime frame: Up to approximately 24 weeks
- Stage A: Percentage of Participants With Antidrug Antibodies (ADA) as a Measure of Immunogenicity Following Multiple Ascending Dose of ABBV-916Time frame: Up to approximately 24 weeks
- Stage B: Change in Brain Amyloid Plaque Deposition (Amyloid Centiloid Value)Time frame: Baseline (Week 0) through Week 24
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Tucson Neuroscience Research /ID# 244957
Tucson, Arizona
Irvine Clinical Research /ID# 239469
Irvine, California
Artemis Institute for Clinical Research - San Diego /ID# 244508
San Diego, California
Pacific Research Network, Inc. /ID# 244083
San Diego, California
Syrentis Clinical Research /ID# 239682
Santa Ana, California
Aventura Neurological Associates /ID# 243892
Aventura, Florida
Charter Research - Lady Lake /ID# 244657
Lady Lake, Florida
JEM Research Institute /ID# 239122
Lake Worth, Florida
ClinCloud - Maitland /ID# 244507
Maitland, Florida
ClinCloud LLC - Viera/Melbourne /ID# 240635
Melbourne, Florida
Merritt Island Medical Research /ID# 239495
Merritt Island, Florida
Optimus U /ID# 245868
Miami, Florida
Finlay Medical Research /ID# 245996
Miami, Florida
Allied Biomedical Res Inst Inc /ID# 244823
Miami, Florida
Renstar Medical Research /ID# 240153
Ocala, Florida
K2 Medical Research - Ocoee /ID# 246849
Ocoee, Florida
K2 Medical Research - Orlando - South Orlando Avenue /ID# 243919
Orlando, Florida
Charter Research - Winter Park /ID# 244778
Orlando, Florida
Headlands Research - Orlando /ID# 239119
Orlando, Florida
Neurology Associates Ormond Beach /ID# 245527
Ormond Beach, Florida
IMIC Inc. Medical Research /ID# 245900
Palmetto Bay, Florida
Alzheimer's Research and Treatment Center - Stuart /ID# 245477
Stuart, Florida
Alzheimer's Research and Treatment Center - Wellington /ID# 245201
Wellington, Florida
Premiere Research Institute - Palm Beach /ID# 240108
West Palm Beach, Florida
Clinical Site Partners (CSP) - Orlando /ID# 245127
Winter Park, Florida
Conquest Research /ID# 243916
Winter Park, Florida
Columbus Memory Center /ID# 245054
Columbus, Georgia
QUEST Research Institute /ID# 239459
Farmington Hills, Michigan
Advanced Memory Research Institute of NJ /ID# 239533
Toms River, New Jersey
Keystone Clinical Studies LLC /ID# 239973
Plymouth Meeting, Pennsylvania
Clinical Trials of Texas, Inc /ID# 244917
San Antonio, Texas
Re:Cognition Health - Fairfax VA /ID# 239501
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.